KRAS and Hepatic fibrosis: Thus, DAA therapies without NS3/4A protease inhibitors such as ledipasvir, an NS5A inhibitor, plus sofosbuvir, a nucleotide type NS5B polymerase inhibitor are recommended to be done in patients with extended liver fibrosis [19].